I D Markl - JoVE Visualize

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Cancer Research|December 16, 1998

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancerI D Markl, P A Jones

Cancer Research|August 2, 2001

Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over timeI D Markl, J Cheng, G Liang, et al.

Genes, Chromosomes & Cancer|August 5, 2000

Bladder cancer genotype stability during clinical progressionJ L Tsao, Y Yatabe, I D Markl, et al.

International Journal of Cancer|June 22, 2000

PAX6 methylation and ectopic expression in human tumor cellsC E Salem, I D Markl, C M Bender, et al.

Genes, Chromosomes & Cancer|May 23, 1998

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targetsG J Walker, J F Flores, J M Glendening, et al.

Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Cancer Research|December 16, 1998

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancerI D Markl, P A Jones

Cancer Research|August 2, 2001

Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over timeI D Markl, J Cheng, G Liang, et al.

Genes, Chromosomes & Cancer|August 5, 2000

Bladder cancer genotype stability during clinical progressionJ L Tsao, Y Yatabe, I D Markl, et al.

International Journal of Cancer|June 22, 2000

PAX6 methylation and ectopic expression in human tumor cellsC E Salem, I D Markl, C M Bender, et al.

Genes, Chromosomes & Cancer|May 23, 1998

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targetsG J Walker, J F Flores, J M Glendening, et al.

Pageof 1